Source: Eur Respir J, 56 (3) 2002182; 10.1183/13993003.02182-2020
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Emmanuel Stephen-Victor, Mrinmoy Das, Anupama Karnam, Bruno Pitard, Jean-François Gautier, Jagadeesh Bayry. Potential of regulatory T-cell-based therapies in the management of severe COVID-19. Eur Respir J, 56 (3) 2002182; 10.1183/13993003.02182-2020

Member's Comments

No comment yet.

Related content which might interest you: Recommendations of new therapies for severe asthma and the future Source: Annual Congress 2013 –ERS/ATS Task Force report on severe asthma Year: 2013 Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017 Clinical implications and novel therapies Source: International Congress 2018 – Accelerated ageing in lungs Year: 2018 Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008 Recommended new therapies for severe asthma and the future Source: International Congress 2014 – PG05 Severe asthma – highlights from the ERS/ATS workshop Year: 2014 Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19 Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020 Year: 2020 Novel targets and emerging therapies in MPM Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 Current and future preventive and treatment strategies in CLAD Source: International Congress 2015 – When chronic inflammation drives fibrosis: a lesson from lung transplantation Year: 2015 A pragmatic guide to choosing biologic therapies in severe asthma Source: Breathe, 17 (4) 210144; 10.1183/20734735.0144-2021 Year: 2021 COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007 Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022 Alternative immunosuppressive strategies Source: ERS Course 2016 Year: 2016 COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020 Year: 2020 Genes, mechanisms and new therapies for asthma Source: Lung Science Conference 2010 - Biology of gene-environment interactions in the lung Year: 2010 Translational research approaches for finding new therapeutic targets involved in viral-induced asthma and COPD exacerbation Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD Year: 2014